HomeAll New Products Listed Chronologically

All New Products Listed Chronologically

Catalog No. Product Name Information Isotype
E1728 STC-15 STC-15 is an oral, small-molecule inhibitor of RNA methyltransferase METTL3. It inhibits tumor growth through the activation of anti-cancer immune responses associated with increased interferon signaling and synergizes with T-cell checkpoint blockade. Apr 16 2024
E1904 SKF-34288 hydrochloride SKF-34288 hydrochloride(3-Mercaptopicolinic acid hydrochloride, 3-MPA hydrochloride) is an orally active, specific inhibitor of phosphoenolpyruvate carboxykinase (PEPCK) with Ki values of 2-9 μM. SKF-34288 hydrochloride is a potent hypoglycemic agent by inhibiting glucose synthesis. SKF-34288 hydrochloride also inhibits cell proliferation, induces myogenic differentiation in vitro. Apr 14 2024
E1036 BMS-986278 BMS-986278 is a potent and orally active antagonist of lysophosphatidic acid receptor 1 (LPA1). BMS-986278 exhibits Kbs of 6.9 nM and 4.0 nM for human and mouse LPA1, respectively, and is widely used in the research of pulmonary fibrotic diseases. Apr 14 2024
S9716 H3B-8800 H3B-8800 is a potent and orally active modulator of SF3B splicing. H3B-8800 interacts directly with the SF3b complex, demonstrating anti-cancer properties. H3B-8800 holds promise for studying acute myeloid leukemia (AML) with SF3B1 mutations. Apr 10 2024
E1597 RMC-6236 RMC-6236 (RAS-IN-2) is a RAS(ON) multi-selective noncovalent inhibitor of the active, GTP-bound state of both mutant and wild-type variants of canonical RAS isoforms with broad therapeutic potential. RMC-6236 exhibits strong anticancer efficacy in RAS-addicted cell lines, especially those with mutations at codon 12 of KRAS. Apr 10 2024
E1880 OTUB2-IN-1 OTUB2-IN-1 is a specific inhibitor of OTUB2, decreases PD-L1 protein expression in tumor cells, leading to suppressed tumor growth through enhanced infiltration of cytotoxic T lymphocytes (CTLs) within the tumor microenvironment. Apr 10 2024
E1903 SLU-PP-332 SLU-PP-332 is an agonist of pan-Estrogen Receptor/ERR with EC50 values of 98nM, 230nM, and 430 nM for ERRα, ERRβ, and ERRγ, respectively with the highest potency for ERRα. SLUPP-332 amplifies mitochondrial function and cellular respiration in skeletal muscle cell lines and also offers opportunities for researching metabolic ailments and enhancing muscle functionality. Apr 10 2024
E1876 GTS-21 dihydrochloride GTS-21 dihydrochloride(DMXB-A, DMBX-anabaseine) is a selective agonist of alpha7 nicotinic acetylcholine receptor (α7-nAChR) and exhibits anti‑inflammatory and cognition‑enhancing activities. GTS-21 dihydrochloride is also an antagonist of α4β2 with a Ki value of 20 nM for humanα4β2 and 5-HT3A receptor with an IC50 value of 3.1 μM. Apr 10 2024
E1924 TI17 TI17 is an inhibitor of thyroid hormone receptor-interacting protein Trip13. TI17 efficiently suppresses the proliferation of multiple myeloma (MM) cells and triggers cell cycle arrest and apoptosis. Trip13, an AAA-ATPase involved in double-strand break (DSB) repair, is targeted by TI17, leading to impaired function and heightened DNA damage. Apr 10 2024
E1710 LY2780301 LY2780301 is a highly selective adenosine triphosphate (ATP)-competitive dual inhibitor of p70S6K and Akt. LY2780301 binds to Akt, inhibiting its activity, which consequently blocks the PI3K/Akt signaling pathway which leads to reduced cell proliferation and the initiation of apoptosis in tumor cells. Apr 08 2024
E1849 TL12-186 TL12-186 is a cereblon-dependent multi-kinase PROTAC degrader. TL12-186 also inhibits CDK2/cyclin A and CDK9/cyclin T1 with IC50 values of 73 nM and 55 nM, respectively. Apr 08 2024
S8267 RapaLink-1 RapaLink-1, a third-generation bivalent inhibitor of mTOR, combines Rapamycin with MLN0128 using an inert chemical linker. It demonstrates efficacy against resistant mutants of malignant brain tumors and inhibits cancer cell progression by binding to mesenchymal markers. Apr 06 2024
E1653 CCT241533 hydrochloride CCT241533 hydrochloride is an ATP competitive, potent, and selective inhibitor of CHK2 with an IC50 of 3 nM and a Ki of 1.16 nM and shows minimal cross-reactivity against a panel of kinases. CCT241533 inhibits CHK2 activity in human tumor cell lines when subjected to DNA damage. Apr 06 2024
E1905 Nalidixic acid sodium salt Nalidixic acid sodium salt is an inhibitor of bacterial DNA gyrase and topoisomerase IV, essential enzymes for DNA supercoiling during replication, making it an effective quinolone antibiotic against both gram-positive and gram-negative bacteria. Apr 06 2024
A2160 Anti-rat Kappa Immunoglobulin Light Chain-InVivo Anti-rat Kappa Immunoglobulin Light Chain-InVivo reacts with the kappa chain of the rat immunoglobulin light chain. The κ chain is one of two types of polypeptide subunits which make up the immunoglobulin light chain. Apr 03 2024
A2161 Anti-mouse ICOSL (CD275)-InVivo Anti-mouse ICOSL (CD275)-InVivo reacts with mouse ICOSL (inducible T cell co-stimulator ligand) also known as CD275, B7RP-1, and B7-H2. ICOSL is a 40 kDa immune checkpoint protein belonging to the Ig receptor superfamily. Apr 03 2024
E1781 Biricodar Biricodar(VX-710) is a modulator of P-glycoprotein and MRP-1 with minimal in vivo toxicity. It enhances the effectiveness of various antibiotics against numerous gram-positive pathogens and exhibits potent chemosensitizing properties in cells resistant to multiple drugs. Mar 31 2024
E1554 Tefinostat(CHR-2845) Tefinostat(CHR-2845) is a monocyte/macrophage-targeted inhibitor of pan-histone deacetylase (HDAC). Tefinostat undergoes cleavage mediated by the intracellular esterase human carboxylesterase-1 (hCE-1) to yield the active acid CHR-2847. In vitro studies reveal a specific heightened sensitivity of monocytoid leukemias to tefinostat. Mar 27 2024
E1783 Conteltinib(CT-707) Conteltinib(CT-707) is a potent multikinase inhibitor of ALK, FAK,Pyk2, showing promising anti-tumor activities. Conteltinib exhibits significant inhibitory effects on FAK with an IC50 value of 1.6 nM in vitro kinase assay. Mar 26 2024
E1114 Ifebemtinib Ifebemtinib(IN10018, BI853520) is a highly selective, potent inhibitor of focal adhesion kinase (FAK), with an IC50 of 1 nM for inhibiting FAK autophosphorylation. It also inhibits FER Kinase and FES Kinase with IC50s of 900 nM and 1040 nM, respectively, inhibiting spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma. IN10018 exhibits anti-tumor activity in vitro and in vivo. Mar 25 2024